GCP
TRVI icon

GSA Capital Partners’s Trevi Therapeutics TRVI Stock Holding History

GSA Capital Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$233K Buy
+12,520
New +$182K 0.01% 1456
2025
Q4 		– Sell
-43,506
Closed -$398K – 2094
2025
Q3 		$398K Buy
+43,506
New +$326K 0.03% 1010
2025
Q1 		– Sell
-120,212
Closed -$495K – 2083
2024
Q4 		$495K Sell
120,212
-2,235
-2% -$7.15K 0.04% 897
2024
Q3 		$409K Buy
+122,447
New +$364K 0.03% 1044

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

GSA Capital Partners's TRVI Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 12,520 shares worth $233K. The stake represents 0.01% of the portfolio and ranks #1456 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in TRVI as recently as Q3 2025.

GSA Capital Partners first reported a position in TRVI in Q3 2024 and has held it in 4 quarters since. The position peaked at $495K in Q4 2024. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • GSA Capital Partners held 12,520 shares of Trevi Therapeutics worth $233K as of Q2 2026.
  • Trevi Therapeutics was a new GSA Capital Partners position in Q2 2026.
  • Trevi Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1456 holding.
  • GSA Capital Partners first reported a position in Trevi Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • GSA Capital Partners's Trevi Therapeutics position peaked at $495K in Q4 2024.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.